NG
NGNE.US Neurogene Inc
- Market cap
- USD 495M
- P/E
- -
- P/B
- 1.40x
- ROE
- -35.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NGNE.US undervalued?
Graham numberThe Graham number of Neurogene Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neurogene Inc fundamental analysis
No fundamental analysis for Neurogene Inc yet.
Neurogene Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., …
Full company profileNeurogene Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neurogene Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 25.0M | - | - | 0.00 | 0.00 | 0.00 | 925K | 0.00 | 0.00 |
| Gross Profit | - | - | 25.0M | -340K | -1.82M | -42.3M | -3.20M | -3.26M | -2.32M | -3.19M | - |
| Operating Income | -37.6M | -51.1M | -23.5M | -24.4M | -41.6M | -50.5M | -56.5M | -55.6M | -82.6M | -103M | -137M |
| EBITDA | -37.0M | -50.2M | -31.6M | -69.1M | -31.5M | -49.6M | -52.0M | -33.0M | -71.9M | -87.3M | -123M |
| Net Income | -37.0M | -50.2M | -31.6M | -69.4M | -33.3M | -50.5M | -55.2M | -36.3M | -75.1M | -90.4M | -126M |
| EPS | -1.96 | -2.14 | -1.34 | -2.57 | -0.64 | -0.92 | -4.30 | -2.83 | -4.28 | -4.27 | -4.55 |
| Balance Sheet | |||||||||||
| Total Assets | 154M | 110M | 77.6M | 147M | 211M | 101M | 109M | 223M | 336M | 289M | 378M |
| Total Liabilities | 9.72M | 11.4M | 4.95M | 5.34M | 19.3M | 193M | 10.6M | 36.5M | 25.4M | 23.7M | 23.1M |
| Shareholders' Equity | 145M | 98.9M | 72.7M | 142M | 191M | -91.9M | 98.6M | 186M | 310M | 265M | 355M |
| Cash & Short-term Investments | 103M | 108M | 76.9M | 143M | 193M | 70.5M | 82.0M | 197M | 312M | 269M | 360M |
| Total Debt | 47.0K | 33.0K | 6.00K | 1.21M | 12.1M | 6.43M | 4.69M | 16.3M | 12.4M | 9.89M | 7.55M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -30.2M | -44.7M | -31.6M | -15.4M | -24.6M | -46.4M | -52.8M | -51.4M | -70.6M | -77.2M | -105M |
| Capital Expenditure | 713K | 494K | 49.0K | 879K | 2.22M | 18.4M | 2.23M | 321K | 808K | 1.18M | 1.27M |
| Free Cash Flow | -30.9M | -45.2M | -31.6M | -16.3M | -26.8M | -64.8M | -55.1M | -51.7M | -71.4M | -78.4M | -107M |
| Ratios | |||||||||||
| ROE | -25.6% | -50.7% | -43.5% | -49.0% | -17.4% | - | -56.0% | -19.5% | -24.2% | -34.1% | -35.5% |
| ROA | -24.0% | -45.5% | -40.7% | -47.2% | -15.8% | -49.8% | -50.5% | -16.3% | -22.4% | -31.3% | -33.3% |
| Net Profit Margin | - | - | -126.3% | - | - | - | - | - | -8,123.7% | - | - |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.01x | 0.06x | - | 0.05x | 0.09x | 0.04x | 0.04x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Neurogene Inc dividends
Neurogene Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Dec 19, 2023.
Who owns Neurogene Inc
- Insiders 8.76%
- Institutions 91.24%
- Public & others 0.00%
- Shares outstanding 20.7M
- Free float 12.0M
Top funds holding NGNE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 521K | 2.52% | 0.00% | Sep 2026 |
| PGIM Jennison Small Company A | 515K | 2.49% | +704.67% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 409K | 1.98% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 393K | 1.90% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 287K | 1.38% | +2.69% | Oct 2026 |
| T. Rowe Price Small-Cap Stock | 264K | 1.27% | -0.57% | Sep 2026 |
| PGIM Jennison Health Sciences Z | 225K | 1.09% | +78.40% | Sep 2026 |
| Franklin Biotechnology Discovery A | 219K | 1.06% | 0.00% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 177K | 0.86% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 152K | 0.73% | 0.00% | Oct 2026 |
| T. Rowe Price Instl Small-Cap Stock | 143K | 0.69% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 131K | 0.64% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 124K | 0.60% | -0.19% | Oct 2026 |
| Fidelity Small Cap Index | 124K | 0.60% | 0.00% | Aug 2026 |
| Fidelity Enhanced Small Cap Core ETF | 112K | 0.54% | +0.27% | Oct 2026 |
| Vanguard Russell 2000 ETF | 91.3K | 0.44% | +40.39% | Sep 2026 |
| Fidelity Extended Market Index | 72.6K | 0.35% | +33.84% | Sep 2026 |
| Meridian Small Cap Growth Legacy | 55.4K | 0.27% | -27.02% | Sep 2026 |
| International Biotechnology Ord | 52.3K | 0.25% | 0.00% | Jul 2026 |
| Fidelity Select Biotechnology | 51.1K | 0.25% | 0.00% | Aug 2026 |
Top institutions holding NGNE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 1.72M | 8.30% | 0.00% | Jun 2026 |
| Casdin Capital, LLC | 1.55M | 7.47% | +8.80% | Jun 2026 |
| Redmile Group, LLC | 1.41M | 6.82% | -3.25% | Jun 2026 |
| RTW INVESTMENTS, LLC | 1.36M | 6.58% | 0.00% | Jun 2026 |
| EcoR1 Capital, LLC | 1.27M | 6.14% | 0.00% | Jun 2026 |
| BlackRock Inc | 1.06M | 5.11% | +5.26% | Jun 2026 |
| Baker Bros Advisors LP | 992K | 4.79% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 819K | 3.96% | +13.96% | Jun 2026 |
| Trails Edge Capital Partners, LP | 715K | 3.45% | -8.67% | Jun 2026 |
| The Toronto-Dominion Bank | 681K | 3.29% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 537K | 2.59% | +4.23% | Jun 2026 |
| Jennison Associates LLC | 519K | 2.51% | -1.73% | Jun 2026 |
| Citadel Advisors Llc | 409K | 1.98% | +5.67% | Jun 2026 |
| Great Point Partners LLC | 352K | 1.70% | -29.56% | Jun 2026 |
| ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 342K | 1.65% | -34.75% | Jun 2026 |
| FMR Inc | 296K | 1.43% | -22.76% | Jun 2026 |
| Geode Capital Management, LLC | 293K | 1.42% | +5.08% | Jun 2026 |
| State Street Corp | 224K | 1.08% | -28.33% | Jun 2026 |
| Franklin Templeton Inc | 204K | 0.99% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 192K | 0.93% | -32.78% | Jun 2026 |
Neurogene Inc company profile
- Company name
- Neurogene Inc
- Ticker
- NGNE.US
- Exchange
- USA Stocks
- Listed since
- Mar 7, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 131
- Fiscal year end
- December
- Address
- 535 W 24th Street, New York, NY, United States, 10011
- Phone
- 855 508 3568
- Website
- neurogene.com
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Neurogene Inc management
10- Dr. Rachel L. McMinn Ph.D.Founder, Executive Chair & CEO · born 1973
- Ms. Christine Mikail Cvijic J.D.President, CFO & Director · born 1978
- Dr. Julie Jordan M.D.Chief Medical Officer · born 1972
- Dr. Stuart Cobb Ph.D.Chief Scientific Officer · born 1971
- Ms. Lina LiExecutive Director of Investor Relations
- Ms. Donna M. Cochener-Metcalfe J.D., L.L.M.Senior VP, General Counsel & Corporate Secretary · born 1975
- Dr. Andrew E. Mulberg CPI, FAAP, M.D.Senior VP of Regulatory Affairs, Quality Assurance & Quality Control
- Mr. Ricardo JimenezSenior Vice President of Technical Operations
- Mr. Arvind SreedharanSenior Vice President of Business Operations
- Ms. Christina ShaferChief Commercial Officer · born 1976